Status:

COMPLETED

Platelet-rich Plasma for Thumb Carpometacarpal Joint Osteoarthritis

Lead Sponsor:

Mayo Clinic

Conditions:

Thumb Carpometacarpal Joint Osteoarthritis

Eligibility:

All Genders

18-80 years

Brief Summary

The purpose of this study is to investigate a case series of patients treated with Platelet-rich plasma for thumb carpometacarpal joint osteoarthritis. Carpometacarpal arthritis is a highly prevalent ...

Detailed Description

The first carpometacarpal (CMC) joint at the base of the thumb is one of the most commonly affected joints by osteoarthritis (OA), with a prevalence ranging from 15-36% in females and 5-11% in males. ...

Eligibility Criteria

Inclusion

  • \- Patients who previously underwent PRP injection of their first CMC joint.

Exclusion

  • \- Individuals less than 18 years of age.

Key Trial Info

Start Date :

October 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 2 2021

Estimated Enrollment :

170 Patients enrolled

Trial Details

Trial ID

NCT04886349

Start Date

October 1 2020

End Date

April 2 2021

Last Update

May 14 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

Platelet-rich Plasma for Thumb Carpometacarpal Joint Osteoarthritis | DecenTrialz